Zaynich (cefepime/zidebactam) / Wockhardt - LARVOL DELTA

Activity of novel antibiotics against dual metallo-Beta-lactamase producing Enterobacter hormaechei clinical isolates. (PubMed, JAC Antimicrob Resist) - "Our findings indicate that E. hormaechei clinical isolates co-producing NDM and VIM metallo-carbapenemases exhibited susceptibility to all tested novel BL/BLIs, including aztreonam/avibactam, cefepime/taniborbactam and cefepime/zidebactam. The combination of cefiderocol and xeruborbactam restored the activity of cefiderocol."

Journal • Infectious Disease

NDM Escherichia coli with aztreonam/avibactam and/or cefiderocol resistance in immunocompromised paediatric patients and use of cefepime/zidebactam (ESCMID Global 2026) - No abstract available

Clinical • Pediatrics

Real-world experience with compassionate use of zidebactam/cefepime (ZID/FEP) in patients with Gram-negative bacterial infections lacking safe and effective treatment options (ESCMID Global 2026) - No abstract available

Clinical • Gram negative • Real-world • Real-world evidence • Infectious Disease

WCK 5222: a case report highlighting a solution for colistin-heteroresistant infection (ESCMID Global 2026) - No abstract available

Case report • Clinical • Infectious Disease

A case series of compassionate use of novel antibiotic WCK 5222 (zidebactam/cefepime) in treatment of diverse infections caused by metallo-β-lactamase (MBL) producing Gram-negative pathogens (ESCMID Global 2026) - No abstract available

Clinical • Gram negative • Infectious Disease

Assessment of impact of variation in standard in vitro testing parameters including physiologically relevant conditions on zidebactam/cefepime MICs (ESCMID Global 2026) - No abstract available

Preclinical

Isolates from zidebactam/cefepime (ZID/FEP) compassionate use under the genomic lens: continued in vitro activity of ZID/FEP against diverse XDR Gram-negative pathogens (ESCMID Global 2026) - No abstract available

Gram negative • Preclinical • Infectious Disease

Multi-centre assessment of zidebactam/cefepime (WCK 5222) MIC test strips (MTS; Liofilchem, Italy) in comparison with reference broth microdilution MIC method (ESCMID Global 2026) - No abstract available

Clinical

Zidebactam/cefepime (ZID/FEP): determination of ZID and FEP pharmacodynamic targets against MDR/XDR P. aeruginosa in neutropenic murine lung infection model (ESCMID Global 2026) - No abstract available

PK/PD data • Preclinical • Infectious Disease • Respiratory Diseases

Safety and tolerability of zidebactam/cefepime (ZID-FEP, WCK 5222) vs meropenem in adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) in a global, randomised, double-blind phase III (Enhance 1) trial (ESCMID Global 2026) - No abstract available

Clinical • P3 data • Infectious Disease • Nephrology

Resistance-suppression potential of zidebactam/cefepime (WCK 5222) against MDR and carbapenem-resistant Enterobacterales: mutant prevention and resistance frequency (ESCMID Global 2026) - No abstract available

In vitro activity of cefepime/zidebactam against ceftazidime/avibactam-resistant Klebsiella pneumoniae isolates carrying blaKPC variants (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease • Pneumonia

In vitro activity of cefepime/enmetazobactam and cefepime/zidebactam against OXA-48-like producing Klebsiella pneumoniae clinical strains (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease • Pneumonia

Zidebactam/cefepime (ZID/FEP): determination of ZID and FEP pharmacodynamic targets against carbapenem-resistant Enterobacterales (CREs) in a neutropenic murine lung infection model (ESCMID Global 2026) - No abstract available

PK/PD data • Preclinical • Infectious Disease • Respiratory Diseases

Evaluation of bactericidal activity of novel β-lactam enhancer/ β-lactam combination: zidebactam/cefepime (ZID/FEP) against NDM-producing Pseudomonas aeruginosa with ZID/FEP MICs greater than 8/8 mg/L (ESCMID Global 2026) - No abstract available

In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates. (PubMed, J Antimicrob Chemother) - "These results demonstrate that cefepime/zidebactam exhibited potent in vitro antibacterial activity against CRAB producing OXA carbapenemase and support its clinical use against both sulbactam/durlobactam-susceptible or -resistant isolates."

Journal • Preclinical

Wockhardt has successfully filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222 on January 5, 2026. (Scanx) - "The company filed the marketing application with the EMA, which serves as the regulatory authority for pharmaceutical products across 27 European Union member states and three European Economic Area countries—Iceland, Liechtenstein, and Norway."

EMA filing • Infectious Disease

Wockhardt has announced that it has been informed by the European Medicines Agency (EMA) that WCK 5222, a combination of Zidebactam 1g plus Cefepime 2g, is eligible for Accelerated Assessment, following a pre-submission meeting with the EMA review team. (Medical Dialogues) - "During the scientific review discussions, EMA noted the novel ẞ-lactam enhancer mechanism of action of WCK 5222 and its relevance in overcoming plethora of resistance mechanisms in Gram-negative bacteria. Based on the totality of available non-clinical, clinical and pharmacokinetic-pharmacodynamic (PK-PD) data, EMA has concurred that WCK 5222 is eligible for accelerated assessment pursuant to Article 14 (9) of Regulation (EC) no 726/2004."

European regulatory • Infectious Disease

In vitro activity of Cefepime/Enmetazobactam and Cefepime/Zidebactam against OXA-48-producing Klebsiella pneumoniae clinical strains. (PubMed, New Microbiol) - "Our results demonstrated that both enmetazobactam and zidebactam significantly enhanced the bactericidal activity of cefepime in vitro. Based on these findings, we suggest that these combinations could be considered a valuable therapeutic approach for treatment of infections caused by OXA-48-producing K. pneumoniae."

Journal • Preclinical • Infectious Disease • Pneumonia

In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales. (PubMed, J Antimicrob Chemother) - "This study support the use of cefepime-enmetazobactam against ESBL/OXA-48-like co-producers. Cefepime-taniborbactam may be use against KPC and VIM producers and could represent a second-line option for NDM. Cefepime-zidebactam shows the most promising activity against MBLs, although already emerging resistance calls for caution."

Journal • Preclinical • Infectious Disease • Pneumonia

Wockhardt Ltd. announced that the United States Food and Drug Administration (US FDA) has formally accepted the New Drug Application (NDA) for its novel, first-in-class antibiotic Zaynich. (Indian Pharma Post)

FDA filing • Infectious Disease

First report of treatment-emergent resistance to cefepime-zidebactam in Pseudomonas aeruginosa. (PubMed, Clin Infect Dis) - "During treatment cefepime-zidebactam MICs increased from 8/8 to 32/32mg/L. Whole-genome sequence analysis showed new mutations in the MexAB-OprM efflux operon that were associated with cross-resistance to ceftazidime-avibactam and imipenem-relebactam."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales: an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol. (PubMed, J Antimicrob Chemother) - "CR non-CPE exhibit heterogeneous resistance profiles, especially in ESBL/AmpC co-producers and CTX-M-33-producing isolates. While cefepime-zidebactam, imipenem-relebactam, and cefiderocol were the most active agents, susceptibility testing remains essential to guide therapy in this emerging and neglected bacterial group."

Journal • Preclinical

The company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (USFDA) for its novel antibacterial agent Zidebactam-Cefepime injection... (The Economic Times) - "The NDA submission follows the successful completion of a pivotal Phase III global clinical trial, conducted across 64 sites in India, the USA, Bulgaria, Estonia, Lithuania, Poland, Slovakia, Mexico, and China, it added."

FDA filing • Infectious Disease

How I manage patients with New Delhi metallo-beta-lactamase and OXA-48-producing Enterobacterales infections: a practical approach. (PubMed, Curr Opin Infect Dis) - "Optimal management of NDM- and OXA-48-producing Enterobacterales requires individualized approach guided by pathogen type, resistance profile, and patient characteristics. Improved diagnostics and surveillance are essential to guide early treatment, while novel agents may enhance therapeutic options in the near future."

Journal • Infectious Disease